The Innovation Exchange
Step into the spotlight. Leave with momentum.
This is your shot to stand in front of the people who can fund you, partner you, or pass! The Innovation Exchange puts early-stage biotech companies in front of the people who can actually move them forward. Capital, partners, and strategic attention, all in one room.
If you are building a company that needs funding, partnerships, or visibility to scale, this is your moment to show up with intent.
The Innovation Exchange is a curated, high-visibility pitch session embedded within the main agenda of Advanced Therapies Europe. Launched in 2025, this is where therapeutic developers step onto a main stage and pitch directly to investors, pharma, and dealmakers actively looking for what’s next in cell and gene therapy.
Qualification: Pre-seed to Series A therapeutic developers.
Six selected companies will pitch live to a room of senior decision-makers, alongside a panel of leading investors and pharma partners who are there to evaluate, challenge, and engage.
You present your company. Investors ask the questions that matter. The room is watching.
If you stand out, you leave with more than attention, you leave with momentum.
Finalists receive:
Venture Associate at UCB Ventures
Rahul is an Associate at UCB Ventures. He has a keen interest in working with innovative biotechnology startups and has supported UCB investments in ViaNautis Bio, Iris Medicine and Seamless Therapeutics. Prior to joining UCB, he was a strategy consultant at Adelphi and has been part of several biotechnology research and healthcare finance projects as Amgen Scholar at Beijing and Mitacs Scholar at Montreal. Rahul holds a Bachelor’s degree in Bioengineering from Indian Institute of Technology, Delhi and a PhD degree from the University of Manchester. He is also a Chartered Financial Analyst (CFA®).
Partner at Advantary Capital Partners
Gadareth Higgs, PhD, is a seasoned expert with over 15 years of postgraduate experience in bioinformatics, consulting, and healthcare. As a Due Diligence Analyst Partner at Advantary Capital Partners, he contributes to the firm’s mission of combining deep operational expertise with strategic investment insight to help portfolio companies thrive. Through Higgs Insights, he has helped clients double investor interest, raise funding (up to $7.5M for one and ~$15M collectively), prepare for pitches in only four days, and secure a $1M LP commitment. His warm investor intros package has over a 50% success rate since inception last June.
Principal at Invivo Partners
Bachelor of Science in Biomedical Sciences (UB), Master of Science in Business Management applied to the Biotechnology Sector and Pharmaceutical Industry, specialized in Project Management (BBI) and Postgraduate course in Financing (UPF Barcelona School of Management). Principal at Invivo Partners, having joined the firm in 2020. She is Observer of the Board of Directors at Peptomyc, Integra, Telomere Therapeutics and EsoBiotec. Previously a Project Manager at UPF Ventures, an innovation management firm owned by Universitat Pompeu Fabra. She usually collaborates with different agents of the health innovation ecosystem as an evaluator of innovation projects and start-ups (COMB, EIT Health, CIMTI, The Collider, among others).
Analyst at Ysios Capital
Based in Barcelona, Malgorzata joined Ysios Capital in 2022 as an Investment Analyst, bringing over 15 years of experience in life sciences. Her scientific background spans RNA therapeutics, gene regulation, and genetic diseases. Prior to joining the firm, she was a senior researcher at the Centre for Genomic Regulation (CRG) in Barcelona. She has authored 17 high-impact publications, including first-author papers in Nature and Science, and has been awarded the Marie Curie and Juan de la Cierva fellowships. Malgorzata holds a PhD in Molecular Biology from ICGEB/University of Cambridge and degrees in Biotechnology from the Technical University of Lodz.
Want a preview of the ATE community?
See who was in the room this year and the organisations leading the way in advanced therapies.
Download the 2025 Attendee List
)
)
)
)
)
)
)
)
)
)
